Dizziness

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Hip, Marketing, European Commission, Shoulder, MRI, INN, Fatigue, Movement, Dopamine, ATC, Allergy, International, European, Headache, Disease, Weakness, Syndrome, Nausea, Language, Brain, Somnolence, Dizziness, L-DOPA, Ropinirole, Restless legs syndrome, Abdomen, Red, Parkinson's disease, Thigh, Select, Committee, Patient, Cell, Time, Pramipexole, Anatomy, Medicine, Vomiting, IIA, Magnetic resonance imaging, CHMP, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Blood pressure, Patient, Medical Subject Headings, Marketing, European Commission, Agency, INN, Weight, Constipation, Risk, ATC, Weight loss, Blood, International, Diet, BMI, European, Diabetes, Method, Nausea, Language, Brain, Bupropion, Heart, Dizziness, Naltrexone, Body mass index, Appetite, Food, Kidney, Tablet, Interim, Xerostomia, Select, Human, Safety, Risk management, Anatomy, Medicine, Seizure, Pleasure, Vomiting, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Diarrhea, Marketing, Platinum, INN, Peritoneum, Constipation, Fatigue, Woman, Ovarian cancer, ATC, Insomnia, Hypertension, Capsule, International, Cough, Tubing (recreation), Weakness, Headache, Disease, Nausea, Neutropenia, Language, DNA, Mouth, Cancer, Neoplasm, Thrombocytopenia, Abdomen, Dizziness, Platelet, PARP, Neutrophil, Appetite, European Medicines Agency, Back pain, Uterus, Enzyme, Select, Cell, Patient, Time, Safety, Anatomy, Anemia, Arthralgia, Vomiting, IIA, Periodic breathing

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Medical Subject Headings, Marketing, Diplopia, Agency, INN, Risk, ATC, International, Population, Headache, Ageing, Nausea, Sodium, Brain, Language, Mouth, Seizure, Dizziness, European Medicines Agency, Nervous system, Tablet, Select, Safety, Generalized tonic–clonic seizure, Anatomy, IIA, Carbamazepine, Medical device

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Platinum, INN, Risk, HER2, Leukopenia, Heartburn, Woman, BRCA, Man, Nausea, DNA, Cancer, Neoplasm, Mutation, Pancreatic cancer, ADP, Prostate, Anatomy, Cell division, Cough, IIA, Diarrhea, Prostate cancer, HRD, Fatigue, Breast cancer, ATC, Platelet, Pancreas, Prednisone, Disease, Genome, Abdomen, Testosterone, PARP, Neutrophil, Bevacizumab, Appetite, Human, Anemia, Patient, Medical Subject Headings, Peritoneum, International, FIGO, Tubing (recreation), Neutropenia, Language, Castration, Dizziness, Thrombocytopenia, BRCA1, Gene, Tablet, Select, Time, Vomiting, Ovary, Prednisolone, X-ray, Ovarian cancer, Headache, BRCA2, European Medicines Agency, Indigestion, Periodic breathing, Birth control

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024
Medical Subject Headings, Hip, Marketing, European Commission, Shoulder, MRI, INN, Fatigue, Movement, Dopamine, ATC, Allergy, International, European, Headache, Disease, Weakness, Syndrome, Nausea, Language, Brain, Somnolence, Dizziness, L-DOPA, Ropinirole, Restless legs syndrome, Abdomen, Red, Parkinson's disease, Thigh, Select, Committee, Patient, Cell, Time, Pramipexole, Anatomy, Medicine, Vomiting, IIA, Magnetic resonance imaging, CHMP, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, January 3, 2024
Quality of life, Leukopenia, URTI, Constipation, Lower respiratory tract infection, IND, Insomnia, CD8, Diarrhea, PD-1, DVT, Anemia, Gastroenteritis, Tremor, Fatigue, Common, CD4, Nausea, Multiple myeloma, Neutropenia, Abdominal pain, Therapy, Lenalidomide, Pharmacokinetics, Weakness, Dizziness, Thrombocytopenia, Cytotoxic T cell, Dexamethasone, Appetite, Periodic breathing, Bortezomib, Toxicity, Back pain, Patient, Safety, Peripheral edema, Deep vein thrombosis, Vomiting, Cough, Rash, Bronchitis

Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date. Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks. In comparison, adverse events in these patients observed during a prior regimen containing Revlimid® included nausea, vomiting, deep vein thrombosis (DVT), upper respiratory tract infections (URTI), anemia, and fatigue. None of the more common side effects of lenalidomide (Revlimid®), which include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor, have been observed with STAR-LLD. Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects. These data suggest that STAR-LLD may prove to be superior in tolerability to oral Revlimid, expanding the number of patients that get the full Revlimid® benefit and improving quality of life.

Key Points: 
  • Patient acceptance of self-administration using the ambulatory pump for lenalidomide delivery has been confirmed in this study.
  • Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date.
  • Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks.
  • Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects.

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Urine, Medical Subject Headings, Marketing, INN, Risk, Fracture, Alkaline phosphatase, Woman, Allergy, Heart rate, Vitamin D, ATC, Hypercalcaemia, Menopause, International, Diet, Parathyroid hormone, Headache, Disease, Osteosarcoma, Nausea, Blood, Language, Calcium, Osteoblast, Palpitations, Cancer, Heart, Dizziness, Abdomen, European Medicines Agency, Spine, Back pain, Hypercalciuria, Select, System, Safety, Cardiovascular disease, Anatomy, Arthralgia, Bone fracture, Female, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Inovelon, rufinamide, Date of authorisation: 16/01/2007, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Liver, Lennox–Gastaut syndrome, Medical Subject Headings, Fungal infection, Marketing, Triazole, INN, Fatigue, Allergy, ATC, International, Headache, Disease, Ageing, Language, Blood, Sodium, Brain, Profile, Seizure, Dizziness, Water, European Medicines Agency, Learning disability, Food, Tablet, Select, Human, Anatomy, Somnolence, Vomiting, IIA, Medical device

Human medicines European public assessment report (EPAR): Inovelon, rufinamide, Date of authorisation: 16/01/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Inovelon, rufinamide, Date of authorisation: 16/01/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Constipation, Leukopenia, Risk, Woman, Tremor, Nausea, Cancer, Infection, Back pain, Anatomy, Cough, IIA, Chills, Diarrhea, Fever, ATC, Insomnia, Bone marrow, Pain, Disease, Philadelphia chromosome, Edema, Neutrophil, Human, Safety, ALL, Water, Anemia, Tumor lysis syndrome, Leukemia, Blood pressure, Patient, Medical Subject Headings, Febrile neutropenia, Agency, MRD, Antibody, Cytokine release syndrome, International, Neutropenia, Blood, Language, Dizziness, Thrombocytopenia, Nervous system, Select, Vomiting, CD3, Acute leukemia, Headache, Swelling, Hypoesthesia, Confusion, European Medicines Agency, Cell, CD19, Paresthesia, Rash, Medical device

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised